Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Author Archives: Mission IR

Chanticleer Holdings, Inc. (HOTR) Sets Grand Opening Date of Hooters(R) Restaurant in Budapest, Hungary for August 27, 2012

Posted on August 9, 2012 by Mission IR

Chanticleer Holdings, Inc., a minority owner in the privately-held parent company of the Hooters® brand, Hooters of America (“HOA”), and a franchisee of international Hooters® restaurants, announced today its first Hooters® restaurant in Budapest, Hungary will celebrate its grand opening … Continue reading →

Posted in Chanticleer Holdings Inc. HOTR | Leave a comment

University General Health System, Inc. (UGHS) Announces Acquisition of Houston Area Clinics

Posted on August 1, 2012 by Mission IR

University General Health System, Inc., a diversified, integrated multi-specialty health delivery system, today announced that it has completed the acquisition of diagnostic imaging, physical therapy and sleep clinics in Kingwood, Texas, a suburb of Houston, for a combination of stock, … Continue reading →

Posted in University General Health System Inc. UGHS | Leave a comment

AMRI Burlington Contracted As Aseptic Fill Manufacturer for Market Introduction of Excellagen® Wound Care Product

Posted on June 5, 2012 by Mission IR

AMRI announced today that its Burlington site was contracted by Cardium Therapeutics and its subsidiary, Tissue Repair Company (“Cardium”) to manufacture sterile pre-filled syringes in support of the U.S. introduction of Excellagen®, a professional-use, formulated collagen-based product for the management … Continue reading →

Posted in Cardium Therapeutics Inc. CXM | Leave a comment

Cardium Therapeutics Inc. (CXM) to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences

Posted on May 17, 2012 by Mission IR

Cardium Therapeutics today announced that Christopher J. Reinhard, Chairman & CEO will present a corporate overview and participate in a Regenerative Medicine Panel being held at the Sachs 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences … Continue reading →

Posted in Cardium Therapeutics Inc. CXM | Leave a comment

Cardium Therapeutics Inc. (CXM) Reports New Catheter-Based Methods Significantly Boost Cardiac Gene Delivery In Late-Breaking Presentation at 2012 American Society of Gene & Cell Therapy Meeting

Posted on May 16, 2012 by Mission IR

Cardium Therapeutics today announced a late-breaking poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 15th Annual Meeting being held May 16-19, 2012 at the Pennsylvania Convention Center in Philadelphia, PA. (Photo: http://photos.prnewswire.com/prnh/20120516/LA07787) (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) The new … Continue reading →

Posted in Cardium Therapeutics Inc. CXM | Leave a comment

Cardium Therapeutics Inc. (CXM) Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion

Posted on May 15, 2012 by Mission IR

Cardium Therapeutics today announced an agreement with UK-based Angel Biomedical Limited, a subsidiary of Angel Biotechnology Holdings plc (AIM: ABH), a global biopharmaceutical contract manufacturer, covering the manufacture of formulated collagen for Cardium’s Excellagen® product, which was recently cleared for … Continue reading →

Posted in Cardium Therapeutics Inc. CXM | Leave a comment

Cardium Therapeutics Inc. (CXM) Presents First Quarter 2012 Financial Results and Recent Developments

Posted on May 15, 2012 by Mission IR

Cardium Therapeutics today presented its financial results for the first quarter ended March 31, 2012, and other recent developments. (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) In addition to the announcement of first quarter 2012 financial results, Cardium reported its goals for 2012, which were … Continue reading →

Posted in Cardium Therapeutics Inc. CXM | Leave a comment

Small Biotech Companies Look to Benefit From Improvement of U.S. Patent System

Posted on May 11, 2012 by Mission IR

In recent months the Biotech Industry has become a hotbed of Merger and Acquisition (M&A) activity and speculation. As large pharmaceuticals face major patent expirations in 2012 they have looked to biotech companies to provide new streams of revenue. Given … Continue reading →

Posted in Cardium Therapeutics Inc. CXM | Leave a comment

Cardium Therapeutics Inc. (CXM) Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care

Posted on April 19, 2012 by Mission IR

Cardium Therapeutics is currently exhibiting its new FDA-cleared Excellagen® professional-use, syringe-based wound care product for the management of diabetic foot ulcers, pressure ulcers and other dermal wounds at the 2012 Spring Symposium on Advanced Wound Care (SAWC) being held April … Continue reading →

Posted in Cardium Therapeutics Inc. CXM | Leave a comment

Smith Medical Partners Announces Logistics Agreement for Cardium Therapeutic Inc.’s (CXM) National Distribution of Excellagen™

Posted on April 2, 2012 by Mission IR

Smith Medical Partners, the specialty pharmaceutical subsidiary of H. D. Smith, today announced an exclusive logistics and cold chain services agreement with Cardium Therapeutics, a health sciences and regenerative medicine company, to support its recently launched wound care product, Excellagen™.  … Continue reading →

Posted in Cardium Therapeutics Inc. CXM | Leave a comment